New HIV drug cocktail tested in newborns to block transmission
NCT ID NCT07055451
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing the safety and how the body handles a new combination HIV drug (B/F/TAF) in full-term newborns who were exposed to HIV at birth. The goal is to see if this drug can be used to prevent the babies from getting infected. The study involves 16 infants and focuses on side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF)
What this could lead to
If successful, this could provide a safe and effective way to prevent HIV infection in newborns exposed to the virus.
What could go wrong
This is a very early Phase 1b study with only 16 participants, so results may not apply to all newborns. The drug's safety and effectiveness in this age group are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Durban International Clinical Research Site, Enhancing Care Foundation
Durban, 4013, South Africa
-
Family Centre for Research with Ubuntu (FAMCRU)
Cape Town, 7505, South Africa
-
Grady Health System - Ponce de Leon Center
Atlanta, Georgia, 30308, United States
-
Perinatal HIV Research Unit (PHRU)
Gauteng, 1864, South Africa
-
Ronald Reagan UCLA Medical Center (inpatient hospital)
Los Angeles, California, 90095, United States
-
St Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
WITS RHI Shandukani Research Centre
Johannesburg, 2001, South Africa